ArticleFrontiers in immunology2021
Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARγ Axis in Colitis.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 145 citations in OpenAlex.
- The gut microbiota-tryptophan metabolism-immune axis in inflammatory bowel disease: Mechanisms and therapeutic prospects.Human vaccines & immunotherapeutics · 2026Review
- Stigmasterol ameliorates neurological deficits and neuroinflammation in rats with traumatic brain injury by suppressing STAT3/NF-κB/LCN-2.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Article
- Atriplex portulacoides L. derived phytochemicals mitigate acetic acid induced colitis in rats via orchestrating Nrf2/Keap1 signalling and LncRNAs gene expression.Inflammopharmacology · 2026Article
- Treg/Th Cell Imbalance Is Negatively Associated with Gut Microbiota Dysbiosis and Growth Impairment in Children Exposed to PFAS, PAHs, and Phthalates.Environment & health (Washington, D.C.) · 2026Article
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy.Chinese medical journal · 2026Review
- Butyric Acid-Modified m-P14 Peptide Ameliorates Anti-Glomerular Basement Membrane Disease.International journal of molecular sciences · 2026Article
- Alcohol Intake-Induced Aggravation of Chronic Prostatitis/Chronic Pelvic Pain Syndrome is Associated with Reduced Gut Microbiota-Driven Short-Chain Fatty Acid Propionate and Butyrate.The world journal of men's health · 2026Article
- Metabolic reprogramming in cancer: signaling pathways and therapeutic targets.Molecular cancer · 2026Review
- Distinct effects of different Bacteroides strains on depressive-like behavior via a gut-Th1/Th17 cells-brain axis.Communications biology · 2026Article
- Oral microbiota-driven immune modulation along the oral-gut axis: from local signals to systemic inflammation.NPJ biofilms and microbiomes · 2026Review
- Stigmasterol ameliorates obesity-associated insulin resistance by activating the PPARγ pathway and alleviating oxidative stress.Frontiers in endocrinology · 2026Article
- Gut microbiota in chronic kidney disease-mineral and bone disorder: shared mechanisms, disease-specific signatures, and therapeutic prospects.Frontiers in endocrinology · 2026Review
- Gut microbiota and spleen-strengthening and dampness-dispelling therapies in obesity and related metabolic disorders: key mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- Zengwei Chengqi Decoction Reduces Inflammation in Acute Intestinal Obstruction.Mediators of inflammation · 2026Article
- The immunoregulatory effect of short-chain fatty acids in type 2 diabetes mellitus.Frontiers in nutrition · 2026Review
- Gut microbiota and SCFA signatures in predicting postoperative infection sites in neurocritical care patients.Frontiers in microbiology · 2026Article
- Research advances on the gut-kidney axis theory in sepsis-associated acute kidney injury.Frontiers in pharmacology · 2026Review
- Clostridium butyricum Regulates the Inflammatory and Immunoregulatory Pathway Through NFKB1 in Colorectal Cancer Treatment.Probiotics and antimicrobial proteins · 2026Article
- Atopic dermatitis and the gut-skin axis: a review from dysbiosis to novel targeted therapeutic strategies.Frontiers in immunology · 2026Review
- From microbiome to outcome: the cascading effects of combining acid suppressants with anti-tuberculosis therapy.Frontiers in medicine · 2026Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with gut microbiota disequilibrium and regulatory T (Treg)/T helper 17 (Th17) immune imbalance. Stigmasterol, a plant-derived sterol, has shown anti-inflammatory effects. Our study aimed to identify the effects of stigmasterol on experimental colitis and the related mechanisms. Stigmasterol treatment restored the Treg/Th17 balance and altered the gut microbiota in a dextran sodium sulfate (DSS)-induced colitis model. Transplantation of the faecal microbiota of stigmasterol-treated mice significantly alleviated inflammation. Additionally, stigmasterol treatment enhanced the production of gut microbiota-derived short-chain fatty acids (SCFAs), particularly butyrate. Next, human naïve CD4+ T cells sorted from IBD patients were cultured under Treg- or Th17-polarizing conditions; butyrate supplementation increased the differentiation of Tregs and decreased Th17 cell differentiation. Mechanistically, butyrate activated peroxisome proliferator-activated receptor gamma (PPARγ) and reprogrammed energy metabolism, thereby promoting Treg differentiation and inhibiting Th17 differentiation. Our results demonstrate that butyrate-mediated PPARγ activation restores the balance of Treg/Th17 cells, and this may be a possible mechanism, by which stigmasterol attenuates IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.